Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- FY2022 Drug Price Revision Rate at -6.69% on Pharma Spending Basis
February 4, 2022
- Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Govt Panel Proposes Enhanced Pharma Supply Chain through Economic Security Bill
February 2, 2022
- MHLW Clarifies Position on Investigational Drug Info; No Generic Names Allowed on Companies’ Clinical Trial Websites
February 2, 2022
- DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
- MHLW OKs 115 More COVID-19 Vaccine Health Damage Claims
February 1, 2022
- Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- MHLW Panel Holds Off Decision on Bayer’s CKD Med Kerendia
January 31, 2022
- Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Cost-Effectiveness Analysis Temporarily Halted for Zolgensma to Collect Long-Term Data
January 31, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- MHLW Council Deems Public Knowledge-Based Filings Acceptable for 8 Fertility Treatment Indications
January 28, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…